The DOI matches its Crossref record; 214 of the 215 references it cites were found in a registry or an index; none of the 23 sources its claims cite is checked for support yet.
CDC Guideline for Prescribing Opioids for Chronic Pain—United States, 2016
Open accessAbstract
IMPORTANCE: Primary care clinicians find managing chronic pain challenging. Evidence of long-term efficacy of opioids for chronic pain is limited. Opioid use is associated with serious risks, including opioid use disorder and overdose. OBJECTIVE: To provide recommendations about opioid prescribing for primary care clinicians treating adult patients with chronic pain outside of active cancer treatment, palliative care, and end-of-life care. PROCESS: The Centers for Disease Control and Prevention (CDC) updated a 2014 systematic review on effectiveness and risks of opioids and conducted a supplemental review on benefits and harms, values and preferences, and costs. CDC used the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) framework to assess evidence type and determine the recommendation category. EVIDENCE SYNTHESIS: Evidence consisted of observational studies or randomized clinical trials with notable limitations, characterized as low quality using GRADE methodology. Meta-analysis was not attempted due to the limited number of studies, variability in study designs and clinical heterogeneity, and methodological shortcomings of studies. No study evaluated long-term (≥1 year) benefit of opioids for chronic pain. Opioids were associated with increased risks, including opioid use disorder, overdose, and death, with dose-dependent effects. RECOMMENDATIONS: There are 12 recommendations. Of primary importance, nonopioid therapy is preferred for treatment of chronic pain. Opioids should be used only when benefits for pain and function are expected to outweigh risks. Before starting opioids, clinicians should establish treatment goals with patients and consider how opioids will be discontinued if benefits do not outweigh risks. When opioids are used, clinicians should prescribe the lowest effective dosage, carefully reassess benefits and risks when considering increasing dosage to 50 morphine milligram equivalents or more per day, and avoid concurrent opioids and benzodiazepines whenever possible. Clinicians should evaluate benefits and harms of continued opioid therapy with patients every 3 months or more frequently and review prescription drug monitoring program data, when available, for high-risk combinations or dosages. For patients with opioid use disorder, clinicians should offer or arrange evidence-based treatment, such as medication-assisted treatment with buprenorphine or methadone. CONCLUSIONS AND RELEVANCE: The guideline is intended to improve communication about benefits and risks of opioids for chronic pain, improve safety and effectiveness of pain treatment, and reduce risks associated with long-term opioid therapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
0 of 23 cited sources checked · 0 supported · 0 flagged
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Of primary importance, nonopioid therapy is preferred for treatment of chronic pain. Opioids should be used only when benefits for pain and function are expected to outweigh risks.”
§ CDC Guideline for Prescribing Opioids for Chronic Pain—United States, 2016 > Abstract > RECOMMENDATIONS
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“When opioids are used, clinicians should prescribe the lowest effective dosage, carefully reassess benefits and risks when considering increasing dosage to 50 morphine milligram equivalents or more per day,”
§ CDC Guideline for Prescribing Opioids for Chronic Pain—United States, 2016 > Abstract > RECOMMENDATIONS
None of the sources cited for this claim could be matched to a paper in Crossref, so there is nothing to check it against.
In the paper
“Several nonpharmacologic and nonopioid pharmacologic treatments were found to be effective for chronic pain in studies ranging in duration from 2 weeks to 6 months48–66 (Table 3).”
§ CDC Guideline for Prescribing Opioids for Chronic Pain—United States, 2016 > Guideline Development Process > Contextual Evidence Review
What the sources say
- Not matchedcites [48]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Not matchedcites [49]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Not matchedcites [50]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Not matchedcites [51]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Not matchedcites [52]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Not matchedcites [53]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Not matchedcites [54]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Not matchedcites [55]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Not matchedcites [56]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Not matchedcites [57]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Not matched
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No study evaluated long-term (≥1 year) benefit of opioids for chronic pain.”
§ CDC Guideline for Prescribing Opioids for Chronic Pain—United States, 2016 > Abstract > EVIDENCE SYNTHESIS
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The recommendations in the guideline are voluntary, rather than prescriptive standards. They are based on emerging evidence, including observational studies or randomized clinical trials with notable limitations.”
§ CDC Guideline for Prescribing Opioids for Chronic Pain—United States, 2016 > Abstract > CONCLUSIONS AND RELEVANCE
None of the sources cited for this claim have been checked yet.
In the paper
“Studies examining patients who underwent low-risk surgery or experienced low back pain from injury revealed that opioid therapy prescribed for acute pain was associated with greater likelihood of long-term use.”
§ CDC Guideline for Prescribing Opioids for Chronic Pain—United States, 2016 > Guideline Development Process > Clinical Evidence Review
What the sources say
- Not checked yetcites [46]
- Not checked yetcites [47]
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No study evaluated the effectiveness of risk mitigation strategies.”
§ CDC Guideline for Prescribing Opioids for Chronic Pain—United States, 2016 > Guideline Development Process > Clinical Evidence Review
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Evidence consisted of observational studies or randomized clinical trials with notable limitations, characterized as low quality using GRADE methodology.”
§ CDC Guideline for Prescribing Opioids for Chronic Pain—United States, 2016 > Abstract > EVIDENCE SYNTHESIS
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Opioids were associated with increased risks, including opioid use disorder, overdose, and death, with dose-dependent affects.”
§ CDC Guideline for Prescribing Opioids for Chronic Pain—United States, 2016 > Abstract > EVIDENCE SYNTHESIS
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Before starting opioids, clinicians should establish treatment goals with patients and consider how opioids will be discontinued if benefits do not outweigh risks.”
§ CDC Guideline for Prescribing Opioids for Chronic Pain—United States, 2016 > Abstract > RECOMMENDATIONS
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“A study of almost 100,000 patients found that the average rate of tapering was 34.0% of the original dose per month and more than a quarter of patients were tapering at a rate faster than 40% of their original dose per month,43,49 even higher than the maximum rate recommended by the CDC. 1”
From Tapering and withdrawing opioids: guidance informed by fundamental principles to minimise withdrawal symptoms (2025) · cites this paper as [1]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, opioids are significantly less effective against chronic pain, such as neuropathic pain, fibromyalgia, and low-back pain, and tolerance develops to the analgesic effects of opioids, thus necessitating the need for increasingly higher doses to sustain analgesia (McQuay, 1988;Dowell et al., 2016).”
From Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development (2021) · cites this paper as Dowell et al., 2016
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The influential Centres for Disease Control (CDC) Guideline for Prescribing Opioids recommends a linear reduction of opioid doses: ‘A decrease of 10% of the original dose per week’ or ‘slower tapers (e.g. 10% per month)’ for longer term users (Figure 1(a)). 1”
From Tapering and withdrawing opioids: guidance informed by fundamental principles to minimise withdrawal symptoms (2025) · cites this paper as [1]
In the citing paper
“Opioids are also associated with substantial systemic harm such as worsening psychopathology, addiction, tolerance, and premature death. 24”
From Rome IV Functional Gastrointestinal Disorders and Health Impairment in Subjects With Hypermobility Spectrum Disorders or Hypermobile Ehlers-Danlos Syndrome (2021) · cites this paper as [24]
In the citing paper
“The Centers for Disease Control and Prevention and US Food and Drug Administration issued warnings in 2016 to make prescribers and patients aware of these risks.19,34”
From Patterns in Outpatient Benzodiazepine Prescribing in the United States (2019) · cites this paper as [34]
In the citing paper
“evidence of their longterm efficacy and safety is limited.6”
From Mind-Body Therapies for Opioid-Treated Pain: A Systematic Review and Meta-analysis (2020) · cites this paper as [6]
In the citing paper
“Although opioids are considered to be useful in managing a wide continuum of pain, including acute, procedural, and chronic pain”
From Mind-Body Therapies for Opioid-Treated Pain: A Systematic Review and Meta-analysis (2020) · cites this paper as [6]
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. B. (2013) · Oxford University Press eBooks · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,845
GRADE: an emerging consensus on rating quality of evidence and strength of recommendations
Guyatt, G. H., Oxman, A. D., Vist, G. E., Kunz, R., Falck-Ytter, Y., Alonso-Coello, P., & Schünemann, H. J. (2008) · BMJ · doi:10.1136/bmj.39489.470347.ad · Cited by 23,305
GRADE guidelines: 3. Rating the quality of evidence
Balshem, H., Helfand, M., Schünemann, H. J., Oxman, A. D., Kunz, R., Brozek, J., Vist, G. E., Falck-Ytter, Y., Meerpohl, J., & Norris, S. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2010.07.015 · Cited by 8,285
Kroenke, K., Spitzer, R. L., Williams, J. B. W., & Löwe, B. (2010) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2010.03.006 · Cited by 4,057
GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology
Guyatt, G. H., Oxman, A. D., Schünemann, H. J., Tugwell, P., & Knottnerus, A. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2010.09.011 · Cited by 3,094
Hochberg, M. C., Altman, R. D., April, K. T., Benkhalti, M., Guyatt, G., McGowan, J., Towheed, T., Welch, V., Wells, G., & Tugwell, P. (2012) · Arthritis Care & Research · doi:10.1002/acr.21596 · Cited by 3,068
Zhang, W., Moskowitz, R. W., Nuki, G., Abramson, S., Altman, R. D., Arden, N., Bierma-Zeinstra, S., Brandt, K. D., Croft, P., Doherty, M., et al. (2008) · Osteoarthritis and Cartilage · doi:10.1016/j.joca.2007.12.013 · Cited by 2,796
Chou, R., Qaseem, A., Snow, V., Casey, D., Cross, J. T., Shekelle, P., Owens, D. K., & for the Clinical Efficacy Assessment Subcommittee of the American College of Physicians and the American College of Physicians/American Pain Society Low Back Pain Guidelines Panel* (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-147-7-200710020-00006 · Cited by 2,718
Self-citationCDC Guideline for Prescribing Opioids for Chronic Pain — United States, 2016
Dowell, D., Haegerich, T. M., & Chou, R. (2016) · MMWR. Recommendations and Reports · doi:10.15585/mmwr.rr6501e1 · Cited by 2,697
Self-citationPsychosomatic medicine in Germany: more timely than ever
Zipfel, S., Herzog, W., Kruse, J., & Henningsen, P. (2016) · Psychotherapy and Psychosomatics · doi:10.1159/000447701 · Cited by 2,323
Flagged first, then by citations
1 of the 215 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 1,001–1,036 of 1,036
Canadian Guidelines on Benzodiazepine Receptor Agonist Use Disorder Among Older Adults
Conn, D. K., Hogan, D. B., Amdam, L., Cassidy, K.-L., Cordell, P., Frank, C., Gardner, D., Goldhar, M., Ho, J. M.-W., Kitamura, C., et al. (2020) · Canadian Geriatrics Journal · doi:10.5770/cgj.23.419 · Cited by 32
Tapering opioids: a comprehensive qualitative review
Davis, M. P., Digwood, G., Mehta, Z., & McPherson, M. L. (2020) · Annals of Palliative Medicine · doi:10.21037/apm.2019.12.10 · Cited by 33
Factors associated with opioid-tapering success: A mixed methods study
Kuntz, J. L., Dickerson, J. F., Schneider, J. L., Firemark, A. J., Papajorgji-Taylor, D., Slaughter, M., Reese, K. R., Thorsness, L. A., Sullivan, M. D., Debar, L. L., et al. (2021) · Journal of the American Pharmacists Association · doi:10.1016/j.japh.2020.12.019 · Cited by 33
Garland, E. L., Gullapalli, B. T., Prince, K. C., Hanley, A. W., Sanyer, M., Tuomenoksa, M., & Rahman, T. (2023) · Mindfulness · doi:10.1007/s12671-023-02137-0 · Cited by 34
Social media as an emerging tool for reducing prescription opioid misuse risk factors
Young, S. D., Lee, S.-J., Perez, H., Gill, N., Gelberg, L., & Heinzerling, K. (2020) · Heliyon · doi:10.1016/j.heliyon.2020.e03471 · Cited by 27
Increased Nonopioid Chronic Pain Treatment in the Veterans Health Administration, 2010–2016
Frank, J. W., Carey, E., Nolan, C., Kerns, R. D., Sandbrink, F., Gallagher, R., & Ho, P. M. (2019) · Pain Medicine · doi:10.1093/pm/pny149 · Cited by 28
Opioids and pituitary function: expert opinion
Gadelha, M. R., Karavitaki, N., Fudin, J., Bettinger, J. J., Raff, H., & Ben-Shlomo, A. (2022) · Pituitary · doi:10.1007/s11102-021-01202-y · Cited by 27
Spithoff, S., Mathieson, S., Sullivan, F., Guan, Q., Sud, A., Hum, S., & O'Brien, M. A. (2020) · The Journal of the American Board of Family Medicine · doi:10.3122/jabfm.2020.04.190199 · Cited by 25
Rogers, A. H., Orr, M. F., Shepherd, J. M., Bakhshaie, J., Ditre, J. W., Buckner, J. D., & Zvolensky, M. J. (2021) · Journal of Behavioral Medicine · doi:10.1007/s10865-020-00169-8 · Cited by 25
Ankawi, B., Kerns, R. D., & Edmond, S. N. (2019) · Current Pain and Headache Reports · doi:10.1007/s11916-019-0813-x · Cited by 26
Lam, C., Amarasinghe, G., Zarate-Lopez, N., Fikree, A., Byrne, P., Kiani-Alikhan, S., Gabe, S., & Paine, P. (2023) · Frontline Gastroenterology · doi:10.1136/flgastro-2022-102088 · Cited by 23
Serious opioid-related adverse outcomes associated with opioids prescribed by dentists
Khouja, T., Zhou, J., Gellad, W. F., Mitsantisuk, K., Hubbard, C. C., Yan, C. H., Sharp, L. K., Calip, G. S., Evans, C. T., & Suda, K. J. (2022) · Pain · doi:10.1097/j.pain.0000000000002545 · Cited by 21
Romanelli, R. J., Dolginsky, M., Byakina, Y., Bronstein, D., & Wilson, S. (2017) · Journal of Patient Experience · doi:10.1177/2374373517706837 · Cited by 17
Opioid use in cancer patients compared with noncancer pain patients in a veteran population
Mudumbai, S. C., He, H., Chen, J.-Q., Kapoor, A., Regala, S., Mariano, E. R., Stafford, R. S., Abnet, C. C., Pfeiffer, R. M., Freedman, N. D., et al. (2024) · JNCI Cancer Spectrum · doi:10.1093/jncics/pkae012 · Cited by 19
Opioid tapering in patients with prescription opioid use disorder: A retrospective study
Zhou, K., Jia, P., Bhargava, S., Zhang, Y., Reza, T., Peng, Y. B., & Wang, G. G. (2017) · Scandinavian Journal of Pain · doi:10.1016/j.sjpain.2017.09.005 · Cited by 18
Zgierska, A. E., Burzinski, C. A., Garland, E. L., Lennon, R. P., Jamison, R., Nakamura, Y., Barrett, B., Sehgal, N., Mirgain, S. A., Singles, J. M., et al. (2021) · Contemporary Clinical Trials · doi:10.1016/j.cct.2021.106548 · Cited by 18
Zoorob, M. J. (2018) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.4417 · Cited by 17
Esteve, R., Marcos, E., Reyes-Pérez, Á., López-Martínez, A. E., & Ramírez-Maestre, C. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18063054 · Cited by 17
Mascaro, J. S., Singh, V., Wehrmeyer, K., Scott, B., Juan, J., McKenzie-Brown, A. M., Lane, O. P., & Haack, C. (2021) · PAIN Reports · doi:10.1097/pr9.0000000000000924 · Cited by 14
Herbert, M. S., Afari, N., Robinson, J. B., Listvinsky, A., Bondi, M. W., & Wetherell, J. L. (2018) · The Journal of Pain · doi:10.1016/j.jpain.2018.02.008 · Cited by 15
Exogenous Opioids and the Human Endocrine System: An Endocrine Society Scientific Statement
Karavitaki, N., Bettinger, J. J., Biermasz, N., Christ-Crain, M., Gadelha, M. R., Inder, W. J., Tsourdi, E., Wakeman, S. E., & Zatelli, M. (2024) · Endocrine Reviews · doi:10.1210/endrev/bnae023 · Cited by 14
Mixed Methods Study of Patient and Primary Care Provider Perceptions of Chronic Pain Treatment
Roper, K. L., Jones, J., Rowland, C., Thomas-Eapen, N., & Cardarelli, R. (2021) · Patient Education and Counseling · doi:10.1016/j.pec.2020.08.038 · Cited by 11
Kakko, J., Gedeon, C., Sandell, M., Grelz, H., Birkemose, I., Clausen, T., Rúnarsdóttir, V., Simojoki, K., Littlewood, R., Alho, H., et al. (2018) · Substance Abuse Treatment Prevention and Policy · doi:10.1186/s13011-018-0160-7 · Cited by 10
Ni, W., Ricker, C., Quinn, M., Gasquet, N., Janardhanan, D., Gilligan, C. J., & Hirsch, J. A. (2022) · Osteoporosis International · doi:10.1007/s00198-021-06163-3 · Cited by 10
Breeden, M. A., Jacobs, C. K., Witthaus, M., Salas, J., Everard, K. M., Penton, E., & Scherrer, J. F. (2020) · The Journal of the American Board of Family Medicine · doi:10.3122/jabfm.2020.01.190247 · Cited by 8
Assessing the use of a clinical decision support tool for pain management in primary care
Apathy, N. C., Sanner, L., Adams, M. C. B., Mamlin, B. W., Grout, R. W., Fortin, S., Hillstrom, J., Saha, A., Teal, E., Vest, J. R., et al. (2022) · JAMIA Open · doi:10.1093/jamiaopen/ooac074 · Cited by 9
Characteristics of patients with substance use disorder before and after the Affordable Care Act
Campbell, C. I., Parthasarathy, S., Altschuler, A., Young-Wolff, K. C., & Satre, D. D. (2018) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2018.08.028 · Cited by 7
Kanzler, K. E., Robinson, P. J., McGeary, D. D., Mintz, J., Potter, J. S., Muñante, M., Lopez, E. J., Dougherty, D. M., Hale, W. J., & Velligan, D. I. (2018) · Contemporary Clinical Trials · doi:10.1016/j.cct.2018.01.004 · Cited by 7
Villarreal, Y. R., Stotts, A. L., Paniagua, S. M., Rosen, K., Eckmann, M., Suchting, R., & Potter, J. S. (2020) · Journal of Contextual Behavioral Science · doi:10.1016/j.jcbs.2020.08.011 · Cited by 7
Risk Factors for Self-Harm Ideation among Persons Treated with Opioids for Chronic Low Back Pain
Jamison, R. N., Edwards, R. R., Brown, R., Barrett, B. P., Burzinski, C. A., Lennon, R. P., Nakamura, Y., Schiefelbein, T., Garland, E. L., & Zgierska, A. E. (2023) · The Clinical Journal of Pain · doi:10.1097/ajp.0000000000001161 · Cited by 6
Rönne-Petersén, L., Niemi, M., Walach, H., Lavebratt, C., Yang, L. L., Gerdle, B., Ghafouri, B., & Falkenberg, T. (2024) · PLoS ONE · doi:10.1371/journal.pone.0308924 · Cited by 4
Parisi, A., Zgierska, A. E., Burzinski, C. A., Lennon, R. P., Jamison, R. N., Nakamura, Y., Barrett, B., Edwards, R. R., & Garland, E. L. (2023) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2023.109890 · Cited by 4
Cannabis-Based Products for Chronic Pain: An Updated Systematic Review
Chou, R., Fu, R., Ahmed, A. Y., & Morasco, B. J. (2026) · Annals of Internal Medicine · doi:10.7326/annals-25-03152 · Cited by 4
Self-citationPrice-Haywood, E. G., Burton, J. H., Harden-Barrios, J., Bazzano, A., Shi, L., Lefante, J., & Jamison, R. N. (2024) · Journal of General Internal Medicine · doi:10.1007/s11606-024-08965-7 · Cited by 2
Abie Horowitz, M., Framer, A., Strang, J., & Taylor, D. (2025) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253251371504
Daniel Jason Frasca, D. (2021) · Osteopathic Family Physician · doi:10.33181/13023
Metadata
- Authors
- Dowell, D., Haegerich, T. M., & Chou, R.
- Affiliations
- Centers for Disease Control and Prevention (US)
- Corresponding author
- Dowell, Deborah
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2016-04-19
- Volume
- 315
- Issue
- 15
- Pages
- 1624
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- PMC
- PMC6390846
- OpenAlex
- W2296986887
- Cited by
- 5,161
- References
- 215
- Citations by year
- 2026: 137 · 2025: 233 · 2024: 272 · 2023: 347 · 2022: 407 · 2021: 733 · 2020: 825 · 2019: 762 · 2018: 701 · 2017: 525 · 2016: 214
- FWCI
- 723.61
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- JAMA (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (CC999999)
- Agency for Healthcare Research and Quality
- U.S. Public Health Service (200-2013-M-53890, 15IPA-1505478, 290201200014I)
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
- Health Sciences › Medicine › Anesthesiology and Pain Medicine › Pain Management and Opioid Use
- Health Sciences › Medicine › Anesthesiology and Pain Medicine › Anesthesia and Pain Management
- Keywords
- opioid prescribing, chronic pain, opioid use disorder, opioid overdose, benzodiazepines, prescription drug monitoring programs, buprenorphine, methadone, medication-assisted treatment, low-dose opioids, primary care
- MeSH terms
- Contraindications, Adult, Analgesics, Opioid, Benzodiazepines, Centers for Disease Control and Prevention, U.S., Communication, Drug Therapy, Combination, Goals, Humans, Drug Prescriptions, Primary Health Care, United States, Randomized Controlled Trials as Topic, Treatment Outcome, Withholding Treatment, Chronic Pain, Acute Pain, Prescription Drug Misuse, Observational Studies as Topic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-09-24 (prompt extract-v1).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
